$NKTR, $PRTC end merger talks, blaming media speculation
Nektar Therapeutics Inc. and PureTech Health plc ended talks of a business combination, the companies said Tuesday, because media speculation implied a deal was further along than it was.
Shares of San Francisco-based Nektar closed up Tuesday to $3.555, a mild 6% bump from the middle of last week when whispers of a deal emerged. In that same period, PureTech saw its stock fluctuate from $25.05 last Wednesday to a high of $36.02 Thursday and a low of $23.50 Friday before closing today at $24.01.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Fortune 500 company FIS opens new Jacksonville headquarters in RiversideIn late 2019, FIS committed to bring at least 500 new jobs to Jacksonville within 10 years to increase its local workforce to 1,800 employees. Pozmanter said FIS is already 75% of the way to that goal as of the headquarters opening.
Read more »
Death toll from Nigerian floods tops 500 - ministriesWidespread flooding has killed more than 500 people in Nigeria, left around 90,000 homes under water and blocked food and fuel supplies, two government ministries said in an online posting on Friday.
Read more »
Turn Cointelegraph articles into NFTs — Early access for 500 readersCrypto has come a long way since the Bitcoin blockchain launched back in 2009. Commemorate some of the industry’s biggest moments with our Historical NFT collection, in which every Cointelegraph article can be minted into NFTs.
Read more »
Stock market news today: Dow and S&P 500 updatesShoppers are pulling back as prices climb higher
Read more »
Flooding in Nigeria kills 500, displaces 1.4 million, government saysThe floods have also injured 1,546 people and completely destroyed 70,566 hectares of farmland and 45,249 homes, according to officials.
Read more »
Nektar, PureTech Health pull plug on merger talks - San Francisco Business TimesNektar cut about 500 jobs and decided to sublease 200,000 square feet in San Francisco after a promising cancer drug failed clinical trials earlier this year.
Read more »